TNF and inflammatory bowel disease: Further, the potential economic savings afforded by biosimilar anti-TNF-α medicines may allow for wider improvements to IBD care pathways, such as the expansion of healthcare teams, additional support for patients, shortened waiting times, and harmonization of procedures [54].